Chinese Biotech Start-Up Stemirna Therapeutics Raises $14M Series A Round

Login to View

Stemirna Therapeutics, a Chinese biotech start-up focusing on RNA technology-based drug development, has raised nearly RMB100 million (US$14.16 million) in a serious A round of financing.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in